<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02623010</url>
  </required_header>
  <id_info>
    <org_study_id>0356-15-RMC</org_study_id>
    <nct_id>NCT02623010</nct_id>
  </id_info>
  <brief_title>Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma</brief_title>
  <official_title>Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Following First Line Chemotherapy Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include 30 elderly patients age 60-85 with primary CNS DLBCL . Induction&#xD;
      treatment will include Rituximab and high dose methotrexate protocol (containing at least&#xD;
      methotrexate and one more chemotherapy agent).&#xD;
&#xD;
      Patients with MRI documented response CR or PR will enter the study protocol maintenance&#xD;
      phase which will include continous treatment with Ibrutinib 560 mg day until relapse or&#xD;
      disease progression or occurrence of limiting toxicities&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 elderly patients age 60-85 with primary CNS DLBCL who will achieve response CR or PR will&#xD;
      enter the study protocol maintenance phase.&#xD;
&#xD;
      Induction treatment will include Rituximab and high dose methotrexate protocol (containing at&#xD;
      least methotrexate and one more chemotherapy agent).&#xD;
&#xD;
      Patients with MRI documented response CR or PR will enter the study protocol maintenance&#xD;
      phase.&#xD;
&#xD;
      Maintenance: 28 day cycles of Ibrutinib 560 mg orally once daily until relapse or disease&#xD;
      progression or occurrence of limiting toxicities&#xD;
&#xD;
      Evaluation of response:&#xD;
&#xD;
      Radiologic evaluation by MRI will be performed every 3 months. Neurologic status evaluation&#xD;
      every 2 months Neurocognitive evaluation every 6 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS- progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imbruvica (ibrutinib) will be given as maintenance treatment until relapse or toxicity to 30 elderly PCNSL patients after achieving response to first line treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imbruvica</intervention_name>
    <description>Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment</description>
    <arm_group_label>Single arm</arm_group_label>
    <other_name>Ibrutinib</other_name>
    <other_name>JNJ-54179060</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed PCNSL patients whose age is &gt;60 years and achieved response (CR/PR)&#xD;
             after first line immunochemotherapy treatment&#xD;
&#xD;
          -  Tissue diagnosis is mandatory unless positive cerebrospinal fluid (CSF) cytology or&#xD;
             vitrectomy are diagnostic with no evidence for systemic disease&#xD;
&#xD;
          -  No contraindication for high dose methotrexate (HD-MTX) (adequate renal function)&#xD;
&#xD;
          -  KPS &gt; 40%, ECOG &lt; 3&#xD;
&#xD;
          -  Hematology values must be within the following limits:&#xD;
&#xD;
        Absolute neutrophil count (ANC) ≥ 1000/µl independent of growth factor support Platelets&#xD;
        ≥100,000/µl or ≥50,000/µl if bone marrow involvement independent of transfusion support in&#xD;
        either situation • Biochemical values within the following limits: Alanine aminotransferase&#xD;
        (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) Total&#xD;
        bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic&#xD;
        origin Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockroft Gault≥&#xD;
        40 mL/min&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within 4 weeks of randomization.&#xD;
&#xD;
          -  History of stroke or intracranial hemorrhage within 6 months prior to randomization.&#xD;
&#xD;
          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg,&#xD;
             phenprocoumon).&#xD;
&#xD;
          -  Requires treatment with strong CYP3A inhibitors.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
             arrhythmias, congestive heart failure, or myocardial infarction within 6 months of&#xD;
             Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by&#xD;
             the New York Heart Association Functional Classification.&#xD;
&#xD;
          -  Vaccinated with live, attenuated vaccines within 4 weeks of randomization.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or&#xD;
             active Hepatitis B Virus infection or any uncontrolled active systemic infection&#xD;
             requiring intravenous (IV) antibiotics.&#xD;
&#xD;
          -  Any life-threatening illness, medical condition, or organ system dysfunction which, in&#xD;
             the investigator's opinion, could compromise the subject's safety, interfere with the&#xD;
             absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue&#xD;
             risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osnat Bairey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Hematologist, Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osnat Bairey, MD</last_name>
    <phone>972504065471</phone>
    <email>osnatb@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tali Siegal, MD</last_name>
    <phone>97239377950</phone>
    <email>talisi1@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology Institute</name>
      <address>
        <city>Petah Tikva</city>
        <zip>494192</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osnat Bairey, MD</last_name>
      <phone>972504065471</phone>
      <email>osnatb@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Tali Siegal, MD</last_name>
      <phone>97239377950</phone>
      <email>talisi1@clalit.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2015</study_first_posted>
  <last_update_submitted>March 21, 2021</last_update_submitted>
  <last_update_submitted_qc>March 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Osnat Bairey</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Primary CNS lymphoma</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Elderly</keyword>
  <keyword>Maintenance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

